Inhibition of MDR1 activity and induction of apoptosis by analogues of nifedipine and diltiazem: An in vitro analysis

Investigational New Drugs

Volumn 29, Issue 1, 2011, Pages 98-109

  Viale, Maurizio ^a   Cordazzo, Cinzia ^b   De Totero, Daniela ^a   Budriesi, Roberta ^b   Rosano, Camillo ^a   Leoni, Alberto ^b   Ioan, Pierfranco ^b   Aiello, Cinzia ^a   Croce, Michela ^a   Andreani, Aldo ^b   Rambaldi, Mirella ^b   Russo, Patrizia ^a   Chiarini, Alberto ^b   Spinelli, Domenico ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

1,4 dihydropyridines; Antitumor agents; Apoptosis; Multidrug resistance; Pgp 170

Indexed keywords

2,6 DIMETHYL 4 [2 METHYL 6 TRIFLUOROMETHYLIMIDAZO[2,1 B][1,3]THIAZOL 5 YL] 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLIC ACID DIMETHYL ESTER; 2,6 DIMETHYL 4 [6 (3,4,5 TRIMETHOXYPHENYL)IMIDAZO[2,1 B][1,3]THIAZOL 5 YL] 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLIC ACID DIMETHYL ESTER; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4',6 DIAMIDINO 2 PHENYLINDOLE; 8 (4 CHLOROPHENYL) 5 METHYL 8 [2 PENT 2 EN 1 YL OXY] 8H [1,2,4]OXADIAZOLO[3,4 C][1,4]THIAZIN 3 ONE; CASPASE; DILTIAZEM; DILTIAZEM DERIVATIVE; DOXORUBICIN; FLUORESCEIN ISOTHIOCYANATE; GLYCOPROTEIN P; GLYCOPROTEIN P 170; MULTIDRUG RESISTANCE PROTEIN 1; NIFEDIPINE; NIFEDIPINE DERIVATIVE; PROPIDIUM IODIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL MEMBRANE TRANSPORT; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOFLUOROMETRY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ASSAY; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR TRANSPORT; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANNEXIN A5; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; DILTIAZEM; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMANS; INDOLES; INTRACELLULAR SPACE; NIFEDIPINE; P-GLYCOPROTEIN; PROPIDIUM; STAINING AND LABELING;

EID: 78651106621     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9340-7     Document Type: Article

References (38)

1. A Abolhoda AE Wilson H Ross PV Danenberg M Burt KW Scotto 1999 Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin Clin Cancer Res 5 3352 3356 1:CAS:528:DyaK1MXotV2gs7k%3D 10589744
2. M Kourti N Vavatsi N Gombakis V Sidi G Tzimagiorgis T Papageorgiou D Koliouskas F Athanassiadou 2007 Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia Int J Hematol 86 166 173 1:CAS:528:DC%2BD2sXhtFems7jI 10.1532/IJH97.E0624 17875533
3. S Hille DT Rein M Riffelmann R Neumann J Sartorius A Pfützner CM Kurbacher T Schöndorf M Breidenbach 2006 Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer Anticancer Drug 17 1041 1044 1:CAS:528:DC%2BD28XpvFersbo%3D 10.1097/01.cad.0000231480.07654.b5
4. FJ Sharom 2008 ABC multidrug transporters: structure, function and role in chemoresistance Pharmacogenomics 9 105 127 1:CAS:528:DC%2BD1cXhtFOjsg%3D%3D 10.2217/14622416.9.1.105 18154452
5. B Sarkadi L Homolya G Szakács A Váradi 2006 Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system Physiol Rev 86 1179 1236 1:CAS:528:DC%2BD28Xht1SgtLzK 10.1152/physrev.00037.2005 17015488
6. X Li JP Li HY Yuan X Gao XJ Qu WF Xu W Tang 2007 Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms Meth Find Exp Clin Pharmacol 29 607 617 1:CAS:528:DC%2BD1cXitVKrt7k%3D 10.1358/mf.2007.29.9. 1139054
7. FJ Sharom 2006 Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1) Biochem Cell Biol 84 979 92 1:CAS:528:DC%2BD2sXhs1ygtrc%3D 10.1139/O06-199 17215884
8. MF Fromm 2004 Importance of P-glycoprotein at blood-tissue barriers Trends Pharmacol Sci 25 423 429 1:CAS:528:DC%2BD2cXmtVaht7Y%3D 10.1016/j.tips.2004.06.002 15276711
9. E Mechetner A Kyshtoobayeva S Zonis H Kim R Stroup R Garcia RJ Parker JP Fruehauf 1998 Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin Clin Cancer Res 4 389 398 1:CAS:528:DyaK1cXhtlSmsbs%3D 9516927
10. BL Lum MP Gosland S Kaubisch BI Sikic 1993 Molecular targets in oncology: implications of the multidrug resistance gene Pharmacotherapy 13 88 109 1:STN:280:DyaK3s3is1Gmsw%3D%3D 8097038
11. C Avedaño JC Menéndez 2002 Inhibitors of multidrug resistance to antitumor agents (MDR) Curr Med Chem 9 159 193
12. R Krishna LD Mayer 2000 Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR, and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs Eur J Pharm Sci 11 265 283 1:CAS:528:DC%2BD3cXntF2gtLw%3D 10.1016/S0928-0987(00)00114-7 11033070
13. DR Ferry H Traunecker DJ Kerr 1996 Clinical trials of P-glycoprotein reversal in solid tumors Eur J Cancer 32A 1070 1081 1:CAS:528:DyaK28XksVOntLw%3D 10.1016/0959-8049(96)00091-3 8763349
14. V Fischer A Rodríguez-Gascón F Heitz R Tynes C Hauck D Cohen AE Vickers 1998 The multidrug resistance modulator Valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite Drug Metab Dispos 26 802 811 1:CAS:528:DyaK1cXlsVSqs7Y%3D 9698296
15. C Wandel RB Kim S Kajiji P Guengerich GR Wilkinson AJP Wood 1999 Glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies Cancer Res 59 3944 3948 1:CAS:528:DyaK1MXlsVOltL4%3D 10463589
16. MD Vergouwen M Vermeulen RJ de Haan M Levi YB Roos 2007 Dihydropyridine calcium antagonists increase fibrinolytic activity: a systematic review J Cereb Blood Flow Metab 27 1293 1308 1:CAS:528:DC%2BD2sXnvFCqsLw%3D 10.1038/sj.jcbfm.9600431 17191079
17. S Sahney 2006 A review of calcium channel antagonists in the treatment of pediatric hypertension Paediatr Drugs 8 357 373 10.2165/00148581-200608060- 00004 17154643
18. FA Holmes A Lopez G Mavligit G Fraschini D Frye GN Hortobagyi 1997 Secondary drug resistance in breast cancer: failure to reverse with oral nifedipine Int J Cancer 73 184 186 1:STN:280:DyaK2svnsVCitw%3D%3D 10.1002/(SICI)1097-0215(19971009)73:2<184::AID-IJC3>3.0.CO;2-S 9335439
19. PA Philip S Joel SC Monkman E Dolega-Ossowski K Tonkin J Carmichael JR Idle AL Harris 1992 A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide Br J Cancer 65 267 270 1:STN:280:DyaK387ltlKqsg%3D%3D 1739628
20. X Li WL Lu GW Liang GR Ruan HY Hong C Long YT Zhang Y Liu JC Wang X Zhang Q Zhang 2006 Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice Eur J Clin Invest 36 409 418 1:CAS:528:DC%2BD28Xmtl2htL4%3D 10.1111/j.1365-2362.2006.01643. x 16684125
21. X Li GR Ruan WL Lu HY Hong GW Liang YT Zhang Y Liu C Long X Ma L Yuan JC Wang X Zhang Q Zhang 2006 A novel stealth liposomal topotecan with amlodipine: apoptotic effect is associated with deletion of intracellular Ca2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia J Control Release 112 186 198 1:CAS:528:DC%2BD28XktVWnsL4%3D 10.1016/j.jconrel.2006.01.007 16516327
22. R Budriesi B Cosimelli P Ioan CZ Lanza D Spinelli A Chiarini 2002 Cardiovascular characterization of [1, 4]thiazino[3, 4-c][1, 2, 4]oxadiazol-1-one derivatives: Selective myocardial calcium channel modulators J Med Chem 45 3475 3481 1:CAS:528:DC%2BD38XkvVygtbo%3D 10.1021/jm020815d 12139458
23. R Budriesi E Carosati A Chiarini B Cosimelli G Cruciani P Ioan D Spinelli R Spisani 2005 A new class of selective myocardial calcium channel modulators. 2. Role of the acetal chain in oxadiazol-3-one derivatives J Med Chem 48 2445 2456 1:CAS:528:DC%2BD2MXhslajtrs%3D 10.1021/jm0493414 15801835
24. M Viale C Cordazzo B Cosimelli D de Todero P Castagnola C Aiello E Severi G Petrillo M Cianfriglia D Spinelli 2009 Inhibition of MDR1 activity in vitro by a novel class of diltiazem analogues: towards new candidates J Med Chem 52 259 66 1:CAS:528:DC%2BD1cXhsFWnsLzO 10.1021/jm801195k 19093883 see also SciBX, doi:10.1038/scibx.2009.44
25. R Budriesi P Ioan A Locatelli S Cosconati A Leoni MP Ugenti A Andreani R Di Toro A Bedini S Spampinato L Marinelli E Novellino A Chiarini 2008 Imidazo[2, 1-b]thiazole system: A scaffold endowing dihydropyridines with selective cardiodepressant activity J Med Chem 51 1592 1600 1:CAS:528:DC%2BD1cXisFWlurc%3D 10.1021/jm070681+ 18303827
26. AP Phillips 1949 Hantzsch's pyridine synthesis J Am Chem Soc 71 4003 4007 1:CAS:528:DyaG3MXovFw%3D 10.1021/ja01180a037
27. A Andreani M Granaiola A Leoni A Locatelli R Morigi M Rambaldi V Garaliene W Welsh S Arora G Farruggia L Masotti 2005 Antitumor activity of new substituted 3-(5-imidazo[2, 1-b]thiazolylmethylene)-2-indolinones and study of their effect on the cell cycle J Med Chem 48 5604 5607 1:CAS:528: DC%2BD2MXmsFGjs7k%3D 10.1021/jm050353e 16107161
28. RF Hussain AME Nouri RTD Oliver 1993 A new approach for measurement of cytotoxicity using colorimetric assay J Immunol Methods 60 89 96 10.1016/0022-1759(93)90012-V
29. M Novi M Ottone C Dell'Erba F Barbieri B Chiavarina M Maccagno M Viale 2004 1, 4-Bis(1-naphthyl)-2, 3-dinitro-1, 3-butadiene a novel anticancer compound effective against tumor cell lines characterized by different mechanisms of resistance Oncol Rep 12 91 96 1:CAS:528:DC%2BD2cXlvVeru7c%3D 15201965
30. J Qi CZ Yang CY Wang SB Wang M Yang JH Wang 2002 Function and mechanism of pyronaridine: a new inhibitor of P-glycoprotein-mediated multidrug resistance Acta Pharmacol Sin 23 544 550 1:CAS:528:DC%2BD38XksVGrs7g%3D 12060530
31. WT Beck XD Qian 1992 Photoaffinity substrates for P-glycoprotein Biochem Pharmacol 43 89 93 1:CAS:528:DyaK38Xht1Shtrk%3D 10.1016/0006-2952(92)90665-6 1346496
32. VM Gonzales MA Fuertes C Alonso JM Perez 2001 Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59 657 663
33. JF Kerr CM Winterford BV Harmon 1994 Apoptosis. Its significance in cancer and cancer therapy Cancer 73 2013 2026 1:CAS:528:DyaK2cXksl2lt70%3D 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J 8156506
34. JJ Fuster SM Sanz-González UM Moll V Andrés 2007 Classic and novel roles of p53: prospects for anticancer therapy Trends Mol Med 13 192 199 1:CAS:528:DC%2BD2sXlt1aks7o%3D 10.1016/j.molmed.2007.03.002 17383232
35. A Gadducci S Cosio S Muraca AR Genazzani 2002 Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications Eur J Gynaecol Oncol 23 390 396 1:STN:280:DC%2BD38nnvF2gsA%3D%3D 12440809
36. JM Lerma-Díaz G Hernández-Flores JR Domínguez- Rodríguez PC Ortíz-Lazareno P Gómez-Contreras R Cervantes-Munguía D Scott-Algara A Aguilar-Lemarroy LF Jave-Suárez A Bravo-Cuellar 2006 In vivo and in vitro sensitization of leukemic cells to adriamycin-induced apoptosis by pentoxifylline. Involvement of caspase cascades and IkappaBalpha phosphorylation Immunol Lett 103 149 158 10.1016/j.imlet.2005. 10.019 16388856
37. Y Yoshimoto M Kawada D Ikeda M Ishizuka 2005 Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo Int Immunopharmacol 5 281 288 1:CAS:528: DC%2BD2MXksVWqsQ%3D%3D 10.1016/j.intimp.2004.09.032 15652759
38. S Wu YS Ko MS Teng YL Ko LA Hsu C Hsueh Y Chou CC Liew YS Lee 2002 Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: in vitro and in vivo studies J Mol Cell Cardiol 34 1595 1607 1:CAS:528:DC%2BD38XpsFyiurs%3D 10.1006/jmcc.2002.2110 12505058